GAD-alum immunotherapy in Type 1 diabetes mellitus

Alba E. Morales, Kathryn M. Thrailkill

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Glutamic acid decarboxylase (GAD)-alum (Diamyd ®, Diamyd Medical, Stockholm, Sweden) is an adjuvant-formulated vaccine incorporating recombinant human GAD65, the specific isoform of GAD expressed in human pancreatic β-cells and a major antigen targeted by autoreactive T lymphocytes in Type 1 diabetes mellitus. Intermittent vaccination with this protein is theorized to induce immune tolerance to GAD65, thereby potentially interrupting further β-cell destruction. Hence, clinical trials are ongoing to examine the efficacy and safety of GAD-alum immunotherapy in patients with autoimmune-mediated forms of diabetes, including Type 1 diabetes and latent autoimmune diabetes in adults.

Original languageEnglish
Pages (from-to)323-332
Number of pages10
JournalImmunotherapy
Volume3
Issue number3
DOIs
StatePublished - Mar 2011

Keywords

  • C-peptide
  • GAD-alum
  • LADA
  • autoimmune diabetes
  • rhGAD65
  • β-cell

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint

Dive into the research topics of 'GAD-alum immunotherapy in Type 1 diabetes mellitus'. Together they form a unique fingerprint.

Cite this